Suven Life Sciences peers

Companies like Suven Life Scienceslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹6,967 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SUVEN
FY26
VIMTALABS
FY24
TAKE
FY26
Peer
Average
Valuation — at last close
P/E—28.08×◆ 14.95×21.51×
P/B11.78×◆ 3.60×5.27×4.44× +166%
EV/EBITDA-23.30×13.20×◆ -85.32×-36.06× +35%
Market Cap₹6,967 Cr₹1,152 Cr₹164 Cr₹658 Cr +959%
Growth
Revenue CAGR 3Y-19.30%◆ 14.74%-34.07%-9.66% -100%
Revenue CAGR 5Y-12.00%◆ 8.40%-41.25%-16.43% +27%
Net Income CAGR 3Y—24.20%—24.20%
Revenue YoY (latest Q)91.02%10.09%◆ 73981.22%36995.65% -100%
Net Income YoY (latest Q)-147.71%112.16%◆ 216.76%164.46% -190%
Profitability
EBITDA Margin-3998.80%◆ 27.27%-3.53%11.87% -33788%
Net Income Margin-3884.13%12.89%◆ 20.02%16.45% -23705%
Return on Common Equity-78.80%13.64%◆ 42.11%27.88% -383%
Return on Capital Employed-82.30%◆ 16.16%-7.46%4.35% -1992%
Return on Assets-72.78%10.76%◆ 29.84%20.30% -459%
Credit & Quality
Total Debt/Equity◆ 0.00×0.06×0.00×0.03× -100%
Interest Coverage-1838.51×◆ 24.79×-5.51×9.64× -19172%
Scale — latest FY
Revenue / Total Income₹7.1 Cr₹318 Cr₹54.2 Cr₹186 Cr -96%
Net Income−₹276 Cr₹41 Cr₹10.8 Cr₹25.9 Cr -1166%
Total Assets₹624 Cr₹400 Cr₹36.2 Cr₹218 Cr +186%
EPS₹-12.13₹18.51₹0.74₹9.63 -226%
Book Value per Share₹22.43₹144.2₹2.1₹73.15 -69%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.